Phase 4 N=104 Relapse Prevention With Varenicline
Recurrence · Smoking Cessation · Substance-Related Disorders
Primary: Days to Relapse — 9.1; 16.4 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=212 Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Participants Preferring the Inhaler Based on the Number of Steps Needed to Take the COPD Medication — 73; 20; 7 Percentage of participants — p=<0.001
Phase 4 N=20 U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™
Acne Vulgaris
Primary: Mean Percent Change in Inflammatory Lesion (IL), Non-inflammatory Lesion (NIL), and Total Lesion (TL) Counts From Baseline (BL) (Day 1) to Week (Wk) 8. — -55.93; -52.64…
Phase 4 N=280 Evaluation of Immediate Versus Delayed Loading of Dental Implants With a Modified Surface
Partial Edentulism
Primary: Evaluation of Changes in Crestal Bone Levels Evaluated From Standardized Periapical X-rays Comparing the Immediate and Delayed Loading Procedures in Each Group. — 0.82…
Phase 4 N=60 Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis
Meibomian Gland Dysfunction · Posterior Blepharitis
Primary: Ocular Surface Disease Index — 56.6; 46.4; 48.4 units on a scale
Phase 4 N=112 Efficacy of Calcifediol Supplementation in Asthma Control in Asthmatic Patients With Vitamin D Deficiency (ACViD)
Asthma, Bronchial
Primary: Asthma Control Measured With Asthma Control Test (ACT) — 20.49; 18.23 units on a scale
Phase 4 N=300 Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma
Asthma
Primary: Mean Change From Baseline in Total Asthma Symptom Score (Daytime Plus Night Time) at the End of the Treatment Period 1 (TP1) — -3.01; -3.97 Scores on a scale — p=0.206
Phase 4 N=174 Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients
Type 2 Diabetes
Primary: Percentage Change in Proteinuia — -23; -4 % change from baseline
Phase 4 N=13 Effect of Valproic Acid Concentration on Photic Response
Photosensitive Epilepsy
Primary: Difference in SPR During Placebo and VPA Infusions — 15.917; 14.609 standard photosensitive range (SPR) — p=0.016
Phase 4 N=640 Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical
Osteoarthritis
Primary: Total Blood Loss — 323.59; 271.22 ml
Phase 4 N=207 Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder
Attention Deficit Disorder With Hyperactivity
Primary: ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale) — -7.77; -7.99; -10.66; -4.14 units on a scale — p=<.01
Phase 4 N=45 A Comparison of Intra-op Ketamine vs Placebo in Patients Having Spinal Fusion
Postoperative Pain
Primary: Scores on Questionnaires — 95; 101 points — p=0.86
Phase 4 N=60 A Bioequivalence Study of Idiazole 20mg DR Tabs and PARIET® 20 mg DR Tabs After a Single Oral Dose Administration Under Fasting Conditions in Healthy Adults
Gastrointestinal Diseases
Primary: Mean Maximal Measured Plasma Concentration (Cmax) After a Single Dose — 543.78; 530.34 Nanogram per mL (ng/mL)
Phase 4 N=56 Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users
Menstruation Disturbances
Primary: Bleeding Days — 65.6; 46.9 days
Phase 4 N=285 BLIS - Breastfeeding Levonorgestrel IUD Study
Contraception
Primary: Breastfeeding Continuation Rates at 8 Weeks Postpartum — 88; 86 Participants